相关实验视频
Updated: Jul 9, 2025

09:36
Isolated Pancreatic Islet Treatment and Apoptosis Measurement
Published on: May 2, 2025
349
乌罗立C通过激活Nrf2信号来缓解1型糖尿病中的胰腺β细胞功能障碍
Cheng Luo1, Can Hou2, Danyi Yang3,4
1Department of Cardiovascular Surgery, The Second Xiangya Hospital of Central South University, Changsha, 410011, Hunan Province, PR China.
Nutrition & diabetes
|December 1, 2023
概括
乌罗立C (UC) 通过激活Nrf2信号,保护胰腺β细胞免受1型糖尿病 (T1D) 的自身免疫损伤. 这种机制改善了β细胞的功能,并缓解了T1D的进展.
科学领域:
- 免疫学 免疫学 免疫学
- 内分泌学 在内分泌学.
- 分子生物学分子生物学
背景情况:
- 1型糖尿病 (T1D) 是一种针对胰腺胰岛素生成β细胞的自身免疫性疾病.
- 维护β细胞功能对于管理T1D至关重要.
- 需要阐明潜在的治疗性化合物,如乌罗素C (UC) 的精确机制.
研究的目的:
- 在T1D的背景下,研究乌洛C (UC) 调节胰腺β细胞功能的机制.
- 在相关动物模型中评估UC对T1D的保护作用.
主要方法:
- 非肥胖的糖尿病 (NOD) 小鼠接受了UC治疗,以评估T1D的保护.
- 组织学分析 (血素和欧) 评估了胰岛素炎.
- 葡萄糖刺激胰岛素分泌 (GSIS) 和口服葡萄糖耐受性测试监测了T1D进展.
- MIN6β细胞被暴露在具有或没有UC的炎症性细胞因子中,以评估细胞活力,细胞亡,增殖和DNA损伤.
- 西方斑点和免疫光分析了包括Keap1,Nrf2,HO-1和NQO1.1在内的关键蛋白质.
主要成果:
- 在NOD小鼠中,UC的使用显著降低了糖尿病发病率,胰岛炎和血糖水平,同时改善了胰岛素水平和GSIS.
- 治疗UC保护MIN6细胞免受细胞因子诱导的亡和DNA损伤,并增强了增殖.
- UC抑制了Keap1并提高了Nrf2,HO-1和NQO1的表达,促进了Nrf2的核转移.
- 沉默Nrf2消除了UC对β细胞亡,增殖和胰岛素分泌的保护作用.
结论:
- 乌罗立C (UC) 在1型糖尿病中显示出显著的治疗潜力.
- 通过激活Nrf2信号通路,UC可以提高胰腺β细胞的功能和生存率.
- 通过像UC这样的化合物准Nrf2通路,为T1D治疗提供了一个有希望的策略.
相关概念视频
Cell Specific Gene Expression
13.6K
Multicellular organisms contain a variety of structurally and functionally distinct cell types, but the DNA in all the cells originated from the same parent cells. The differences in the cells can be attributed to the differential gene expression. Liver cells, whose functions include detoxification of blood, production of bile to metabolize fats, and synthesis of proteins essential for metabolism, must express a specific set of genes to perform their functions. Gene expression also varies with...
13.6K
Dipeptidyl Peptidase 4 Inhibitors
190
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
190
Chronic Pancreatitis II: Collaborative Care
92
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
92
Glucagon-like Receptor Agonists
329
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
329

